Omnicell (OMCL) Investor Update summary

Product launch and technology innovation

• Announced the launch of Titan XT, a new enterprise platform with updated hardware, software, and real-time data capabilities for pharmacy automation.

• Titan XT enables plug-and-play device integration, cloud-based analytics, and enhanced safety and efficiency.

• Features include dynamic restock, intelligent alerts, AI-driven decision-making, and advanced security standards.

• Titan XT is designed for large, complex health systems managing extensive medication workflows across multiple locations.

Market positioning and customer transition

• Titan XT will be a full forklift upgrade for customers with aging systems, while newer systems can use XT Extend for cloud capabilities.

• The platform offers a logical migration path to the cloud, supporting both enterprise-wide and granular medication management.

• Titan XT and XT Extend provide multiple pathways for customers based on device age and cloud readiness.

• The market opportunity for Titan XT is estimated at $2.5 billion within the current customer base.

Revenue outlook and business model evolution

• Titan XT is now bookable, with hardware shipments expected in the second half of 2026 and general software availability in early 2027.

• 2026 incremental revenue from Titan XT is expected to be modest due to sales and implementation cycles.

• Hardware will be available via both capital purchase and leasing models; software will follow a subscription model.

• Recurring revenue will be driven by service contracts, specialty business, consumables, and cloud-based software.